Peptide Initiative

Peptides · Peptide comparison

Orforglipron vs Tirzepatide

First oral non-peptide GLP-1 receptor agonist for diabetes and obesity

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeOrforglipron0.8–17.2 mgTirzepatide5–10 mg
FrequencyOrforglipronOnce dailyTirzepatideOnce weekly
AdministrationOrforglipronoralTirzepatideSubcutaneous injection
Cycle lengthOrforglipronOngoing/indefiniteTirzepatideOngoing/indefinite
Onset speedOrforglipronModerate (1-2 weeks)TirzepatideModerate (1-2 weeks)
Evidence levelOrforglipronStrong human trials (Phase 3 or FDA approved)TirzepatideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Management

Orforglipron9%
TirzepatideNo recorded rating

Blood Sugar Control

Orforglipron9%
Tirzepatide96%

Cardiovascular Health

Orforglipron7%
TirzepatideNo recorded rating

Weight Loss

OrforglipronNo recorded rating
Tirzepatide99%

Appetite Control

OrforglipronNo recorded rating
Tirzepatide97%

Technical data

Compound specifications

Orforglipron

Molecular formula
C48H48F2N10O5
Molecular weight
883.0 Da
Half-life
About 29–49 hours (elimination half-life after an oral dose)
Bioavailability
77% absolute oral bioavailability (0.8 mg dose); no clinically relevant food effect
CAS number
2212020-52-3

Tirzepatide

Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2

Protocols

Dosing compared

Orforglipron

Oral

  • At least 30 days0.8 mg once dailyOnce daily, with or without food · At least 30 daysLabel starting dose. After at least 30 days, increase to 2.5 mg once daily, then after at least 30 more days to 5.5 mg once daily; gradual escalation reduces gastrointestinal reactions [7]. Tablets are swallowed whole, one per day [7].
  • Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg5.5 mg once dailyOnce daily, with or without food · Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mgFirst maintenance-level dose on the label's escalation [7]. In the phase 3 trial without diabetes, 5.5 mg produced 7.4% average weight loss at 72 weeks against 2.1% on placebo [7].
  • Ongoing; each step after at least 30 days on the previous dose9–17.2 mg once dailyOnce daily, with or without food · Ongoing; each step after at least 30 days on the previous doseOptional further steps of 9 mg, 14.5 mg and 17.2 mg based on response and tolerability; 17.2 mg is the maximum, and 9 mg is the maximum alongside a strong CYP3A4 inhibitor [7]. 17.2 mg produced 11.1% average weight loss at 72 weeks against 2.1% on placebo [7].

Tirzepatide

Subcutaneous injection

  • First 4 weeks2.5 mgOnce weekly · First 4 weeksFDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
  • Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly · Increase by 2.5 mg after at least 4 weeks at each dosePer FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
  • Ongoing maintenance12.5-15 mgOnce weekly · Ongoing maintenance15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].

Applications

Best suited for

Orforglipron

Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tirzepatide

People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].

Safety profile

Side effects

Orforglipron

Common

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting

Uncommon

  • Heart Rate Increase

Serious

  • Pancreatitis Risk

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Orforglipron

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use — as FOUNDAYO (orforglipron) tablets, on 1 April 2026, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. Not approved for type 2 diabetes.
Safety overview
Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management. [7][8] Its label carries a boxed warning on thyroid C-cell tumours seen with GLP-1 receptor agonists in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. [7] In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent during dose escalation; 8% stopped treatment for adverse reactions against 3% on placebo. [7] Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycaemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration under anaesthesia. [7]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (boxed-warning contraindication) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7]
  • Known hypersensitivity to orforglipron or excipients [7]
  • History of pancreatitis (use with caution)

Tirzepatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
  • History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication

Decision guide

Which is right for you?

Orforglipron

Choose Orforglipron if…

  • Oral GLP-1 receptor agonism without injection burden
  • Weight management in obesity with or without type 2 diabetes
  • Glycemic control in type 2 diabetes as add-on to metformin
  • Cardiovascular risk reduction through weight loss and metabolic improvements

Tirzepatide

Choose Tirzepatide if…

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement